Market Capitalization (Millions $) |
348 |
Shares
Outstanding (Millions) |
281 |
Employees |
- |
Revenues (TTM) (Millions $) |
8 |
Net Income (TTM) (Millions $) |
-26 |
Cash Flow (TTM) (Millions $) |
-40 |
Capital Exp. (TTM) (Millions $) |
1 |
Perspective Therapeutics Inc
Perspective Therapeutics Inc is a biotech company that focuses on developing innovative therapies for various diseases and medical conditions. The company's goal is to provide groundbreaking solutions that improve patient outcomes and quality of life.
They specialize in developing therapeutics that target specific biological pathways and mechanisms to address the underlying causes of diseases. The company's research and development efforts encompass a wide range of therapeutic areas, including oncology, neurology, immunology, and rare genetic disorders.
Perspective Therapeutics Inc utilizes advanced technologies and scientific approaches to identify and develop small molecule drugs, biologics, and gene therapies. The company collaborates with leading academic institutions, research organizations, and pharmaceutical companies to leverage their collective expertise and resources.
Their team consists of experienced scientists, researchers, and clinicians who are dedicated to translating scientific discoveries into clinically relevant treatment options. The company's approach is rooted in rigorous scientific research, preclinical studies, and clinical trials to ensure the safety and efficacy of their therapeutic candidates.
Perspective Therapeutics Inc aims to make a significant impact on the healthcare industry by introducing new and effective treatment options for patients worldwide. Ultimately, their mission is to improve the lives of individuals affected by challenging diseases through innovative therapies that address unmet medical needs.
Company Address: 350 Hills St., Suite 106 Richland 99354 WA
Company Phone Number: 375-1202 Stock Exchange / Ticker: NYSE CATX
CATX is expected to report next financial results on May 14, 2024. |
|
|